Persistent intolerable abdominal pain in patients with Parkinson’s disease

[1]  B. Mollenhauer,et al.  Levodopa Equivalent Dose Conversion Factors: An Updated Proposal Including Opicapone and Safinamide , 2020, Movement disorders clinical practice.

[2]  K. Sugie,et al.  Recent advancements in lateral trunk flexion in Parkinson disease , 2018, Neurology. Clinical practice.

[3]  G. Deuschl,et al.  MDS clinical diagnostic criteria for Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[4]  A. Dupeyron,et al.  Botulinum Toxin-A for treatment of Pisa syndrome: A new target muscle. , 2015, Parkinsonism & related disorders.

[5]  H. Sung,et al.  The Frequency and Severity of Gastrointestinal Symptoms in Patients with Early Parkinson’s Disease , 2014, Journal of movement disorders.

[6]  S. Ueno,et al.  Painful abdominal contractions in patients with Parkinson disease , 2012, Journal of Clinical Neuroscience.

[7]  S. Paek,et al.  Effect of deep brain stimulation on pain in Parkinson disease , 2011, Journal of the Neurological Sciences.

[8]  A. Rana,et al.  Abdominal pain: a symptom of levodopa end of dose wearing off in Parkinson's disease. , 2011, The West Indian medical journal.

[9]  Roy W Jones,et al.  Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial , 2010, The Lancet Neurology.

[10]  H. Braak,et al.  Parkinson's disease: a dual‐hit hypothesis , 2007, Neuropathology and applied neurobiology.

[11]  B. Boeve,et al.  Occurrence and clinical correlates of REM sleep behaviour disorder in patients with Parkinson’s disease over time , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[12]  H. Braak,et al.  Gastric α-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology , 2006, Neuroscience Letters.

[13]  J. Jankovic,et al.  Camptocormia , 2005, Neurology.

[14]  Robert A Hauser.  Levodopa/carbidopa/entacapone (Stalevo) , 2004, Neurology.

[15]  R. Sakakibara,et al.  Colonic transit time and rectoanal videomanometry in Parkinson’s disease , 2003, Journal of neurology, neurosurgery, and psychiatry.

[16]  R. Hauser,et al.  A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients , 1998, Movement disorders : official journal of the Movement Disorder Society.

[17]  W R Woodward,et al.  The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. , 1984, The New England journal of medicine.

[18]  M. Seki,et al.  Japanese translation and linguistic validation of King’s Parkinson’s Disease Pain Scale (KPPS) and King’s Parkinson’s Disease Pain Questionnaire (KPPQ) , 2021, Rinsho Shinkeigaku.